drugset / Trial / NCT02963831
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
Phase 1/2
Completed
67 enrolled
Ludwig Institute for Cancer Research
Cancer Research Institute, New York City · collabMedImmune LLC · collabTargovax ASA · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a two-part Phase 1/2 dose escalation and dose expansion study of an Adenovirus Vector (Ad5/3-D24-GMCSF), Expressing GM-CSF (GM-CSF-encoding adenovirus), ONCOS-102, in combination with anti-programmed death ligand-1 (PD-L1) antibody, durvalumab, in adult subjects with peritoneal disease who have failed prior standard chemotherapy and have histologically confirmed epithelial ovarian cancer or metastatic colorectal cancer.
Timeline
- Start
- 2017-09-07
- Primary completion
- 2022-06-25
- Completion
- 2022-06-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | ONCOS-102 | Unknown | 1e+11 vg | Intrathecal |
| Subject | ONCOS-102 | Unknown | 3e+11 vg | Intrathecal |
| Background | Cyclophosphamide | Other / unclassified | 300 mg | Intravenous |